Skip to main content
. Author manuscript; available in PMC: 2009 Jul 29.
Published in final edited form as: Schizophr Res. 2006 Oct 27;89(1-3):91–100. doi: 10.1016/j.schres.2006.08.017

Table 2.

Frequency of Metabolic Syndrome, Individual Metabolic Syndrome Criteria and Insulin Resistance in Patients Treated with Antipsychotic Monotherapy vs. Antipsychotic Polypharmacy

Characteristic Total (N=364) Antipsychotic Monotherapy (N=294) Antipsychotic Polypharmacy (N=70) F/chi2 P-value
Metabolic syndrome (N, %) 136 (37.4) 101 (34.3) 35 (50.0) χ2: 5.91 0.015
# of metabolic syndrome criteria (±SD) 1.97± 1.3 1.9 ± 1.4 2.2 ± 1.4 F: 1.81 0.18
Waist circumference >102 cm in males or >88 cm in females (N, %) 122 (33.5) 94 (32.0) 28 (40.0) χ2: 1.63 0.20
Triglycerides ≥150 mg/dL (N, %)a 151 (41.6) 117(39.8) 34 (49.3) χ2: 2.07 0.15
Fasting hyperglycemia ≥110 mg/dL (N, %)b 42 (11.6) 35 (11.9) 7(10.1) χ2: 0.18 0.67
Hypertension 130/85 mm Hg (N, %) 173 (47.5) 139 (47.3) 34 (48.6) χ2: 0.038 0.85
HDL <40 mg/dl in males or <50 mg/dl in females (N, %) 212 (58.2) 163 (55.4) 49 (70.0) χ2: 4.93 0.026
Triglyceride/HDL-cholesterol >3.5 (N, %)a 138 (38.0) 103 (35.0) 35 (50.7) χ2: 5.84 0.016
Continuous Metabolic Variables
Waist circumference (cm±SD) 92.2 ± 14.2 91.4 ± 13.7 95.5 ± 16.1 F: 4.84 0.028
Fasting glucose (mg/dL±SD)b 93.1 ±22.5 92.6 ± 22.0 95.0 ± 24.6 F: 0.65 0.42
Systolic blood pressure (mm Hg±SD) 124.0 ± 14.7 123.8 ± 14.3 124.9 ± 16.6 F: 0.32 0.75
Diastolic blood pressure (mm Hg±SD) 79.0 ±9.1 78.8 ± 9.0 79.9 ± 9.7 F: 0.91 0.34
HDL (mg/dl ±SD) 44.8 ± 12.1 45.2 ± 12.3 42.9 ± 10.9 F: 2.09 0.15
Triglycerides (mg/dL±SD)a 136.2 ±81.8 134.2 ±81.3 144.6 ± 83.8 F: 0.91 0.34
Total cholesterol (mg/dL±SD)a 171.4 ±40.1 172.5 ± 39.5 167.0 ±42.3 F: 01.06 0.30
LDL-cholesterol (mg/dL±SD)a 115.5 ±37.2 115.7 ±36.6 114.9 ±39.5 F: 0.03 0.87
Triglyceride/HDL-cholesterol ratio (±SD)a 3.5 ±2.8 3.4 ±2.8 3.7 ±2.5 F: 0.70 0.4
a

: Based on 363 patients with available information;

b

: based on 362 patients with available information